https://www.selleckchem.com/pr....oducts/alkbh5-inhibi
Effective cancer therapeutics for brain tumors must be able to cross the blood-brain barrier (BB to reach the tumor in adequate quantities and overcome the resistance conferred by the local tumor microenvironment. Clinically approved chemotherapeutic agents have been investigated for brain neoplasms, but despite their effectiveness in peripheral cancers, failed to show therapeutic success in brain tumors. This is largely due to their poor bioavailability and specificity towards brain tumors. A targeted delivery system might
Like
Comment
Share
